Novartis AG patent applications published on July 25th, 2024

Summary of the patent applications from Novartis AG on July 25th, 2024

1. **Summary**: Novartis AG has recently filed patents for novel compounds and methods in the pharmaceutical industry. These patents focus on combining GLP-1 compounds with fatty acids, synthesizing pharmaceutical compounds efficiently, and targeting IKAROS Family Zinc Finger 2 (IKZF2) in diseases like cancers. The innovations offer new possibilities for drug development and treatment options, addressing challenges related to existing treatments' efficacy and side effects.

2. **Key Points of Patents**:

  * Novel compounds combining GLP-1 compounds with fatty acids for potential therapeutic benefits.
  * Efficient synthesis methods for pharmaceutical compounds with therapeutic applications.
  * Targeting IKZF2 in diseases like cancers with novel dosing regimens and formulations.

3. **Notable Applications**:

  * Development of new therapies for metabolic disorders and other conditions using GLP-1 and fatty acid compounds.
  * Streamlined approach to synthesizing compounds for potential drug discovery and development.
  * Targeted therapies for IKZF2-dependent diseases, particularly cancers, with the potential for improved patient outcomes and quality of life.

Patent applications for Novartis AG on July 25th, 2024

DOSING REGIMENS (18559859)

Main Inventor

Stephanie Kay DODD

DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES (17415923)

Main Inventor

Simone BONAZZI

Tricyclic Compounds and their Uses (18483651)

Main Inventor

Vincent BORDAS

MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 (18531320)

Main Inventor

Zhongbo Fei

GLUCAGON LIKE PEPTIDE COMPOUNDS (18556461)

Main Inventor

Valerie BEAULIEU